Positive Association of Complement Factor H Gene Variants with the Effect of Photodynamic Therapy in Polypoidal Choroidal Vasculopathy

Abstract

Purpose: To clarify the association of complement factor H (CFH) gene polymorphisms with the effects of photodynamic therapy (PDT) in polypoidal choroidal vasculopathy (PCV).Methods: Ninety-three PCV subjects treated with PDT were recruited. Patients who showed anatomical success after the treatments with a single or two consecutive PDT sessions were classified as PDT responders. All others were classified as non-PDT responders. Three single nucleotide polymorphisms (SNPs), rs800292 (I62V), rs1061170 (Y402H) and rs1410996 were genotyped using the TaqMan assay. Results:The genotype and allelic frequency of rs1061170 (Y402H) and rs1410996 were significantly different between PDT responders and non-responders. In these SNPs, the risk alleles for PCV prevalence were beneficial for PDT response. In the time course analysis, the cases with C/C genotype in rs1410996 showed a significant increase of mean visual acuity at 6 and 12 months after the first PDT. Conclusions:The coding variants in CFH may be associated with the effects of PDT in PCV. genetic variations in the CFH region including Asian populations, and the association between these CFH variants and the ability of PDT to regress PCV in a Japanese population was analyzed.

Polypoidal Choroidal Vasculopathy: Clinical Features and Genetic Predisposition

“…Goverdhan et al [131] also reported the positive association of CFH Y402H with the outcome of PDT in tAMD, but discovered the C allele as the risk allele for a better VA. On the other hand, other studies failed to demonstrate any association of this variant with the outcome of PDT [127,128,130]. In PCV cases, one study demonstrated that the SNPs rs1061170 (Y402H) and rs1410996 in the CFH region were significantly associated with an anatomical response to PDT [132]. Two studies found that the genotype at rs10490924 (A69S) in ARMS2 was significantly associated with the lesion size in PCV patients, as well as the visual outcome in tAMD and PCV patients 12 months after their first PDT [110,133].…”

Salient Features of New Therapies in Ophthalmology

“…A research was done to clarify the association of complement factor H (CFH) gene polymorphisms with the effects of photodynamic therapy (PDT) in Polypoidal Choroidal Vasculopathy (PCV) [11,41,36,45]. The genotype and allelic frequency of rs1061170 (Y402H) and rs1410996 were significantly different between PDT responders and nonresponders.…”